ES2545457T3 - Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 - Google Patents

Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 Download PDF

Info

Publication number
ES2545457T3
ES2545457T3 ES12155448.9T ES12155448T ES2545457T3 ES 2545457 T3 ES2545457 T3 ES 2545457T3 ES 12155448 T ES12155448 T ES 12155448T ES 2545457 T3 ES2545457 T3 ES 2545457T3
Authority
ES
Spain
Prior art keywords
cancers
express
peptide vaccines
peptide
depdc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12155448.9T
Other languages
English (en)
Spanish (es)
Inventor
Tomoaki Fujioka
Yusuke Nakamura
Takuya Tsunoda
Ryuji Osawa
Midori Shida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ES2545457T3 publication Critical patent/ES2545457T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
ES12155448.9T 2006-10-17 2007-10-16 Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 Active ES2545457T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85257506P 2006-10-17 2006-10-17
US852575P 2006-10-17

Publications (1)

Publication Number Publication Date
ES2545457T3 true ES2545457T3 (es) 2015-09-11

Family

ID=39313729

Family Applications (4)

Application Number Title Priority Date Filing Date
ES12155448.9T Active ES2545457T3 (es) 2006-10-17 2007-10-16 Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
ES12155444.8T Active ES2545817T3 (es) 2006-10-17 2007-10-16 Vacunas de péptidos para cánceres que expresan los polipéptidos MPHOSPH1
ES07827901T Active ES2415958T3 (es) 2006-10-17 2007-10-16 Vacunas de péptidos para cánceres que expresan los polipéptidos MPHOSPH1 ó DEPDC1
ES12155446.3T Active ES2545818T3 (es) 2006-10-17 2007-10-16 Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES12155444.8T Active ES2545817T3 (es) 2006-10-17 2007-10-16 Vacunas de péptidos para cánceres que expresan los polipéptidos MPHOSPH1
ES07827901T Active ES2415958T3 (es) 2006-10-17 2007-10-16 Vacunas de péptidos para cánceres que expresan los polipéptidos MPHOSPH1 ó DEPDC1
ES12155446.3T Active ES2545818T3 (es) 2006-10-17 2007-10-16 Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1

Country Status (17)

Country Link
US (5) US8557955B2 (https=)
EP (7) EP2476698B1 (https=)
JP (2) JP5339292B2 (https=)
KR (4) KR101543622B1 (https=)
CN (5) CN102850433B (https=)
AU (1) AU2007311395B2 (https=)
BR (1) BRPI0717651A2 (https=)
CA (2) CA2915560A1 (https=)
DK (1) DK2091965T3 (https=)
ES (4) ES2545457T3 (https=)
IL (4) IL198186A (https=)
MX (1) MX2009004147A (https=)
PL (1) PL2091965T3 (https=)
PT (1) PT2091965E (https=)
RU (1) RU2469044C2 (https=)
SG (2) SG175566A1 (https=)
WO (1) WO2008047473A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
CN101827936B (zh) * 2007-08-20 2014-12-10 肿瘤疗法科学股份有限公司 Cdh3肽以及含有cdh3肽的药剂
US8975086B2 (en) 2008-08-28 2015-03-10 Oncotherapy Science, Inc. Method for treating or preventing bladder cancer using the DEPDC1 polypeptide
BRPI1012312A2 (pt) * 2009-03-04 2017-03-21 Oncotherapy Science Inc peptídeos vangl1 e vacinas incluindo os mesmos
TW201211250A (en) * 2010-09-07 2012-03-16 Oncotherapy Science Inc VANGL1 peptides and vaccines including the same
JP5564730B2 (ja) * 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
JP2013058294A (ja) * 2011-09-09 2013-03-28 Toshiba Corp 磁気記録媒体及び磁気記録媒体の製造方法
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
JP6041297B2 (ja) * 2012-08-24 2016-12-07 国立大学法人山口大学 犬リンパ腫の診断方法及び診断キット
MY177482A (en) * 2013-03-13 2020-09-16 Zhong Li Microvesicle and method for producing the same
SI3132247T1 (sl) 2014-04-16 2021-12-31 Juno Therapeutics Gmbh Postopki, kompleti in naprava za povečanje populacije celic
EP3925968A3 (en) 2014-10-07 2022-03-02 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
CN113388021A (zh) 2015-03-09 2021-09-14 Cytlimic公司 源于gpc3的肽、使用其的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
RU2709015C2 (ru) 2015-04-07 2019-12-13 Ситлимик Инк. Лекарственное средство
CA2994929A1 (en) * 2015-08-12 2017-02-16 Oncotherapy Science, Inc. Depdc1-derived peptide and vaccine containing same
SG11201802286PA (en) 2015-10-08 2018-04-27 Oncotherapy Science Inc Mphosph1-derived peptide, and vaccine including same
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
TW201831503A (zh) * 2016-11-18 2018-09-01 日商腫瘤療法 科學股份有限公司 對於ｔｈ１細胞的ｍｐｈｏｓｐｈ１抗原決定位胜肽及包含其之疫苗
TW201831502A (zh) * 2016-11-18 2018-09-01 日商腫瘤療法 科學股份有限公司 對於ｔｈ１細胞的ｄｅｐｄｃ１抗原決定位胜肽及包含其之疫苗
WO2018094569A1 (zh) * 2016-11-22 2018-05-31 深圳华大基因研究院 多肽及其应用
PL4029494T3 (pl) 2017-01-25 2026-03-23 Ose Immunotherapeutics Sposób wytwarzania stabilnej emulsji do dostarczania peptydów
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
FI3652606T3 (fi) * 2017-07-12 2023-03-16 Nouscom Ag Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon
AU2018384824B2 (en) * 2017-12-13 2022-08-04 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting LEMD1 and uses thereof
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
CN112142824B (zh) * 2019-06-27 2022-03-11 深圳市东贵博康生化科技有限公司 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用
WO2021060343A1 (ja) * 2019-09-24 2021-04-01 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体
ES3001611T3 (en) * 2020-10-15 2025-03-05 Myneo Nv Method, system and computer program product for determining peptide immunogenicity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ZA926441B (en) 1991-08-26 1993-06-07 Cytel Corp HLA-restricted hepatitis B virus CTL epitopes.
EP0534615B1 (en) 1991-08-26 2001-01-03 Epimmune Inc. HLA-restricted hepatitis B virus CTL epitopes
CA2157900A1 (en) * 1993-03-11 1994-09-15 Angeline Douvas Therapeutic strategies for immunoinfective cluster virus infections
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
WO1997005900A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
US20050123938A1 (en) 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
WO2000073801A2 (en) * 1999-05-28 2000-12-07 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
EP1311675B1 (en) 2000-08-22 2007-02-07 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2002031111A2 (en) 2000-10-12 2002-04-18 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2425648A1 (en) * 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046416A2 (en) 2000-12-04 2002-06-13 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2474908A1 (en) * 2002-01-31 2003-08-07 Wyeth Aggrecanase molecules
AU2003222103A1 (en) 2002-03-28 2003-10-13 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN101175862A (zh) * 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
JP2006302684A (ja) 2005-04-21 2006-11-02 D D K Ltd カードコネクタ
EP2295570A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
EP1938104A2 (en) * 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
TWM336439U (en) * 2008-02-14 2008-07-11 Optivision Technology Inc Diffuser capable of light condensing
US8975086B2 (en) * 2008-08-28 2015-03-10 Oncotherapy Science, Inc. Method for treating or preventing bladder cancer using the DEPDC1 polypeptide
JP5564730B2 (ja) 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン

Also Published As

Publication number Publication date
EP2476699B1 (en) 2015-06-17
IL216712A (en) 2017-07-31
EP2687540A1 (en) 2014-01-22
EP2695895A1 (en) 2014-02-12
CN101568550B (zh) 2012-12-26
RU2469044C2 (ru) 2012-12-10
CN102850435A (zh) 2013-01-02
US9017688B2 (en) 2015-04-28
US8552146B2 (en) 2013-10-08
DK2091965T3 (da) 2013-08-05
CA2667030C (en) 2016-03-15
KR101493773B1 (ko) 2015-03-03
SG10201502098YA (en) 2015-05-28
PL2091965T3 (pl) 2013-10-31
CA2667030A1 (en) 2008-04-24
EP2476697A2 (en) 2012-07-18
KR101543622B1 (ko) 2015-08-11
HK1171026A1 (en) 2013-03-15
EP2091965B9 (en) 2013-09-25
US20120282286A1 (en) 2012-11-08
IL216712A0 (en) 2012-01-31
SG175566A1 (en) 2011-11-28
MX2009004147A (es) 2009-06-15
US8557955B2 (en) 2013-10-15
US20100028373A1 (en) 2010-02-04
EP2476698B1 (en) 2015-06-17
HK1171024A1 (en) 2013-03-15
IL216713A0 (en) 2012-01-31
EP2091965B1 (en) 2013-05-15
EP2476697B1 (en) 2015-06-17
CN102850434A (zh) 2013-01-02
PT2091965E (pt) 2013-06-11
KR101454287B1 (ko) 2014-11-04
CN102850434B (zh) 2016-04-13
WO2008047473A1 (en) 2008-04-24
JP2010506826A (ja) 2010-03-04
ES2415958T3 (es) 2013-07-29
EP2476698A3 (en) 2013-11-27
AU2007311395B2 (en) 2013-02-21
AU2007311395A1 (en) 2008-04-24
JP2013116115A (ja) 2013-06-13
CN102850435B (zh) 2016-02-17
BRPI0717651A2 (pt) 2013-12-24
EP2091965A1 (en) 2009-08-26
IL198186A (en) 2017-05-29
KR20140104057A (ko) 2014-08-27
US20130129759A1 (en) 2013-05-23
IL198186A0 (en) 2011-08-01
CN102850433A (zh) 2013-01-02
ES2545817T3 (es) 2015-09-16
EP2476698A2 (en) 2012-07-18
HK1171025A1 (en) 2013-03-15
ES2545818T3 (es) 2015-09-16
KR20090083378A (ko) 2009-08-03
EP2476697A3 (en) 2013-11-27
US20150231222A1 (en) 2015-08-20
KR20140057681A (ko) 2014-05-13
CN102850433B (zh) 2016-03-02
CN101568550A (zh) 2009-10-28
US9545437B2 (en) 2017-01-17
CN105693843A (zh) 2016-06-22
EP2091965A4 (en) 2011-02-16
EP2476699A2 (en) 2012-07-18
IL222925A0 (en) 2012-12-31
HK1131169A1 (en) 2010-01-15
US20120288514A1 (en) 2012-11-15
EP2687541A1 (en) 2014-01-22
EP2476699A3 (en) 2013-11-27
KR101527473B1 (ko) 2015-06-17
US8653234B2 (en) 2014-02-18
RU2009118432A (ru) 2010-11-27
CA2915560A1 (en) 2008-04-24
JP5339292B2 (ja) 2013-11-13
KR20150015042A (ko) 2015-02-09

Similar Documents

Publication Publication Date Title
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
PT2121731E (pt) Vacinas peptídicas para cancros que expressam antigénios associados a tumores
ES2528133T3 (es) Péptidos y composiciones para prevención de la adhesión celular, y métodos para utilizar los mismos
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
PE20230321A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
AR104114A1 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
ES2723774T3 (es) Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
ES2536974T3 (es) Péptidos de epítopos del receptor de EGF y usos de los mismos
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CL2019003406A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
ES2530457T3 (es) Secuencias peptídicas, su forma ramificada y uso de estas para aplicaciones antimicrobianas
ES2572367T3 (es) Péptidos con epítopos de la MELK y vacunas que los contienen
MX2009007261A (es) Vacuna de peptido foxp3.
PE20230343A1 (es) Peptidos que estimulan respuestas inmunitarias antitumorales